Gri Bio Inc (GRI)

Apr 2, 2025, 4:05 PM EDT - 1 day ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 3 days ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:07 AM EDT - 3 days ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Mar 31, 2025, 8:00 AM EDT - 4 days ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 18, 2025, 9:05 AM EDT - 17 days ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 18 days ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 11, 2025, 8:35 AM EDT - 24 days ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 4:05 PM EST - 6 weeks ago

GRI Bio Announces Reverse Stock Split

Feb 19, 2025, 9:00 AM EST - 6 weeks ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 23, 2024, 9:00 AM EST - 3 months ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 6, 2024, 8:35 AM EST - 4 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

Nov 21, 2024, 8:45 AM EST - 4 months ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 5 months ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Oct 24, 2024, 8:30 AM EDT - 5 months ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 5 months ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 6 months ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 6 months ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 6 months ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 7 months ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 7 months ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 14, 2024, 8:05 AM EDT - 8 months ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 15, 2024, 9:05 AM EDT - 9 months ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 9 months ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 9 months ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 9 months ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 9 months ago

GRI Bio to Present at the 8th Annual IPF Summit

Jun 28, 2024, 4:05 PM EDT - 9 months ago

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 27, 2024, 9:00 AM EDT - 10 months ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

May 22, 2024, 9:15 AM EDT - 11 months ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 21, 2024, 8:35 AM EDT - 11 months ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 20, 2024, 8:45 AM EDT - 11 months ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 14, 2024, 9:05 AM EDT - 11 months ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 13, 2024, 8:00 AM EDT - 11 months ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Apr 16, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Apr 8, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Apr 1, 2024, 7:35 AM EDT - 1 year ago

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:00 AM EDT - 1 year ago

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Mar 14, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

Mar 4, 2024, 8:30 AM EST - 1 year ago

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Feb 23, 2024, 7:50 AM EST - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

SINT

Feb 2, 2024, 8:00 AM EST - 1 year ago

GRI Bio Announces Pricing of $5.5 Million Public Offering

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR IBIO VYNE

Dec 5, 2023, 9:05 AM EST - 1 year ago

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Nov 27, 2023, 8:35 AM EST - 1 year ago

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Nov 15, 2023, 8:05 AM EST - 1 year ago

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 31, 2023, 8:45 AM EDT - 1 year ago

GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

Oct 19, 2023, 8:45 AM EDT - 1 year ago

GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference

Oct 17, 2023, 8:35 AM EDT - 1 year ago

GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression